Fate Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Fate Therapeutics, Inc. (NASDAQ: FATE) is a clinical-stage biopharmaceutical company pioneering the development of programmed cellular immunotherapies for cancer and autoimmune diseases. The company leverages its proprietary induced pluripotent stem cell (iPSC) product platform to engineer off-the-shelf, multiplexed-engineered chimeric antigen receptor (CAR) T-cell and natural killer (NK) cell therapies. By utilizing clonal master iPSC lines as a starting cell source, Fate aims to manufacture well-defined, uniform, and scalable cell products that can be stored in inventory and administered to a broad patient population without the limitations of patient- or donor-sourced therapies. Its lead clinical programs include FT819, a CD19-targeted CAR T-cell therapy being evaluated for systemic lupus erythematosus (SLE) and other autoimmune indications, and FT825 / ONO-8250, a HER2-targeted CAR T-cell candidate developed in collaboration with Ono Pharmaceutical for advanced solid tumors.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the potentially registrational Phase 2 clinical trial of FT819 (RECLAIM-LN) targeting refractory moderate-to-severe systemic lupus erythematosus (SLE) with lupus nephritis, utilizing a novel, less-intensive conditioning regimen.
Expected impact: Aims to provide an accessible, outpatient-compatible CAR T-cell treatment option, potentially validating the clinical and commercial viability of the iPSC platform.
Completing IND-enabling activities and establishing the master cell bank for FT839, a next-generation dual-CAR T-cell program targeting autoimmune diseases and hematologic malignancies.
Expected impact: Expands the pipeline into conditioning-free CAR-T therapies, offering a highly differentiated approach for hard-to-treat diseases.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Collaborating to develop and commercialize off-the-shelf CAR-T and CAR-NK cell product candidates derived from engineered master iPSCs for solid tumors.
Terms: Preclinical development activities under the collaboration generated $1.3 million in collaboration revenue for Fate in Q1 2026.
Joint research led by Jeffrey S. Miller, M.D., focusing on the development of off-the-shelf, iPSC-derived CAR NK cell cancer immunotherapies.
Terms: Collaborative research and development activities.